Jagsonpal standalone Q2 and H1 FY27 revenue up about 9%; results approved

Exceptional ItemResults View source PDF Explain this filing

JAGSNPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-6.2%Reaction day

₹236.20

prior close

₹219.52

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%-6.9% vs market

Pharmaceuticals peers, median of 171sector+0.4%-6.6% vs sector

On the reaction day the stock moved 6.9 pts less than Nifty Microcap 250 and 6.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-3.1

10m

-2.3

15m

-1.5

30m

-1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-6.2+0.7-6.9+0.4-6.6

Next day

-9.0pendingpending-0.6-8.4

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 171Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board-approved unaudited September 2026 results show standalone operating revenue up 9.3% at Rs 813.75m in Q2 FY27 and 9.0% at Rs 1,636.07m in H1. Consolidated Q2 revenue was Rs 946.76m and profit Rs 120.85m; H1 revenue was Rs 1,786.03m and profit Rs 254.76m. Cash from operations was positive and the auditor found no material issue. Results include an 85% Aequitas stake bought for Rs 208m on 1 July. Rs 2.35m transaction fees were exceptional.

Likely market impact

Revenue growth, profit and positive cash flow may support sentiment, but the acquisition adds integration risk and makes results harder to compare.